Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis.

Leukemia·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same author

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

HemaSphere·2026
Same author

Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Clinical epigenetics·2026
Same author

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Leukemia·2026

Related Experiment Video

Updated: Jun 19, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Molecular diagnostics in acute leukemias.

Ulrike Bacher1, Susanne Schnittger, Claudia Haferlach

  • 1Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany.

Clinical Chemistry and Laboratory Medicine
|October 13, 2009
PubMed
Summary
This summary is machine-generated.

Molecular diagnostics for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are crucial for prognosis and therapy. This review covers key molecular markers, diagnostic techniques like PCR, and emerging methods such as next-generation sequencing (NGS).

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are heterogeneous cancers.
  • Genetic alterations significantly impact prognosis and treatment decisions.
  • Advances in molecular marker detection have improved understanding of leukemogenesis.

Purpose of the Study:

  • To review important recurrent molecular markers in acute leukemias.
  • To discuss the role of these markers in prognosis and therapy.
  • To provide an overview of relevant molecular diagnostic techniques, including PCR.

Main Methods:

  • Review of current literature on molecular diagnostics in acute leukemias.
  • Discussion of established techniques: cytomorphology, cytogenetics, FISH, MFC, and PCR.
  • Exploration of emerging technologies: next-generation sequencing (NGS) and gene expression profiling.

Main Results:

  • Molecular analysis, including PCR, is essential for acute leukemia diagnosis.
  • Novel mutations (e.g., NPM1 in AML) and targeted therapies (e.g., imatinib for BCR-ABL+ ALL) are key advancements.
  • Quantitative PCR (real-time PCR) enables monitoring of residual disease.

Conclusions:

  • Molecular diagnostics for acute leukemias are rapidly evolving.
  • A combination of traditional and novel molecular techniques is vital for comprehensive diagnosis and management.
  • Continued research into new markers and technologies will further refine treatment strategies.